HDL induces prostacyclin release in smooth muscle cells through the upregulation of Cox-2 expression, providing a potential molecular mechanism for its atheroprotective effects.
Answers are grounded in this paper and cite their sources.
Suggests Cox-2 mediates HDL vascular effects in vitro; leaves open relevance to human atheroprotection.
Cyclooxygenase-1 (Cox-1) and Cox-2 are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. We studied the effects of plasma HDL and LDL on the synthesis of prostacyclin, Cox-1/Cox-2 mRNA, and protein expression by rabbit aortic smooth muscle cells. Prostacyclin synthesis was measured by enzyme immunoassay (EIA) of the stable metabolite of prostacyclin (PGI2), 6-ketoprostaglandin F1 alpha. HDL (150 micrograms/mL) induced release of PGI2 to values 3.46 +/- 0.3-fold above control. Incubations with LDL did not induce release of PGI2. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide (NS-398), a selective irreversible Cox-2 inhibitor, blocked the HDL-induced PGI2 synthesis. Cycloheximide, actinomycin D, and dexamethasone downregulated HDL-induced PGI2 synthesis; therefore, HDL induced de novo synthesis of protein and Cox-2 mRNA. In addition, Northern blot analyses did not reveal differences in Cox-1 mRNA levels between control and HDL-treated cells, whereas Cox-2 mRNA levels were significantly increased in treated cells. Western blot analysis also showed an increase in the levels of Cox-2 protein. Therefore, the effects of HDL on PGI2 synthesis are mediated via upregulation of Cox-2 expression.
No takes yet. Share an insight, caveat, or question.
Viñals et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: